AstraZeneca has recently launched a new global health tech business, Evinova, with the goal of revolutionizing the clinical trial process. The company identified a gap in the market for these services and decided to fill it by creating Evinova.
Evinova will operate as a separate business, providing global services to CROs and pharmaceutical companies to design, run, and monitor clinical trials. The company will charge customers for access to its technology and will operate on a revenue-based model.
By creating Evinova, AstraZeneca aims to address the challenges and inefficiencies in the clinical trial process. This new business venture reflects the company’s commitment to advancing healthcare and utilizing technology to improve the drug development process. With Evinova’s help, patients can participate more easily in clinical trials and contribute to faster and more effective drug development.